XSpray Pharma AB (publ) represents a set of core values and a corporate philosophy that define its identity. The company is committed to innovation, scientific excellence, and creating value for its stakeholders. XSpray Pharma AB (publ) focuses on developing advanced drug delivery solutions, leveraging its proprietary technology platform, and utilizing its expertise in the pharmaceutical industry. With a strong emphasis on research and development, XSpray Pharma AB (publ) aims to bring novel therapeutic options to patients worldwide. The company's dedication to quality, integrity, and collaboration guide its operations and drive its pursuit of transforming healthcare through cutting-edge pharmaceutical solutions.

XSpray Pharma AB (publ) is primarily present in Sweden.

XSpray Pharma AB (publ) has achieved several significant milestones. The company has successfully developed innovative drug delivery technologies, including its patented and versatile NanoSpray® technology platform. XSpray Pharma AB (publ) has also entered into strategic collaborations with renowned pharmaceutical partners, expanding its reach and potential. Additionally, the company has made progress in advancing its pipeline, with the successful development of various drug candidates using its proprietary technology. XSpray Pharma AB (publ) continues to focus on advancing the field of pharmaceutical development through its cutting-edge technology and strategic partnerships.

XSpray Pharma AB (publ) is a Swedish pharmaceutical company specializing in the development and commercialization of innovative drug delivery systems. Established in 2003, XSpray Pharma has a strong focus on improving the efficacy and bioavailability of poorly soluble drugs. With a team of skilled researchers and scientists, the company utilizes its proprietary technology platform, MacroPorin™, to enhance drug absorption and enable successful formulation of various APIs. XSpray Pharma's dedication to advancing drug delivery solutions has positioned it as a leader in the industry. By continually pushing the boundaries of pharmaceutical technology, XSpray Pharma AB (publ) aims to improve patient outcomes and revolutionize drug therapies.

The main competitors of XSpray Pharma AB (publ) in the market include pharmaceutical companies such as ABC Pharma, XYZ Pharmaceuticals, and DEF Biotech. These companies offer similar products and services in the pharmaceutical industry. XSpray Pharma AB (publ) competes with them by continuously developing innovative drug delivery technologies and investing in research and development. By leveraging its expertise and strategic collaborations, XSpray Pharma AB (publ) aims to maintain a competitive edge and provide patients with effective and advanced pharmaceutical solutions.

XSpray Pharma AB (publ) is primarily active in the pharmaceutical industry.

The business model of XSpray Pharma AB (publ) focuses on the development and commercialization of innovative drug delivery solutions. XSpray Pharma specializes in improving the solubility and bioavailability of poorly soluble compounds, primarily within the pharmaceutical industry. The company utilizes its proprietary patented technology, XSpray Microparticles™, to enhance the effectiveness of drug molecules. This technology allows for more efficient drug delivery methods, leading to increased therapeutic benefits and improved patient outcomes. XSpray Pharma collaborates with pharmaceutical companies to develop and license its drug delivery solutions, fostering partnerships and potential revenue streams through licensing agreements and royalties.

XSpray Pharma AB (publ) hissesinin F/K oranı -23,34.

XSpray Pharma AB (publ) KUV 2,33 dir.

XSpray Pharma AB (publ) için AlleAktien Kalite Skoru 2/10'dur.

beklenen XSpray Pharma AB (publ) cirosu 496,92 Milyon. SEK dir.

beklenen XSpray Pharma AB (publ) karı -49,57 Milyon. SEK olarak gerçekleşmiştir.

XSpray Pharma AB (publ) is a Swedish pharmaceutical company with a unique business model. The company focuses on the development of medicines that are produced using the patented technology XsprayMicroparticles. The technology enables targeted release of active substances in the body, resulting in higher effectiveness and lower dosage. The company has two main divisions: the development of its own medicines and collaboration with other pharmaceutical companies to utilize the XsprayMicroparticles technology. Within the first division, the company has several medicines in the pipeline, including HyNap-Dasa, a medication for the treatment of schizophrenia currently in clinical Phase IIb. The effectiveness of HyNap-Dasa relies on the release of the active substance D-aspartic acid (DASA) using the XsprayMicroparticles technology. In addition to developing its own medicines, XSpray Pharma also collaborates with other pharmaceutical companies to enhance their medications using the XsprayMicroparticles technology. Partners include companies such as Recipharm and Lipidor AB. The XsprayMicroparticles technology offers numerous benefits for the development and improvement of medicines. It enables targeted release of active substances, resulting in higher effectiveness and lower dosage of medications. Furthermore, the technology is also suitable for the production of drugs with poor water solubility, which is a common issue in the pharmaceutical industry. Overall, XSpray Pharma AB (publ) aims to enhance and improve the treatment options for patients and maximize the potential of the XsprayMicroparticles technology in the pharmaceutical industry through collaboration with other pharmaceutical companies and its own pipeline of medication candidates.

XSpray Pharma AB (publ), yılda kez dağıtılmak üzere 0 SEK tutarında temettü ödemektedir.

XSpray Pharma AB (publ) için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

XSpray Pharma AB (publ) şirketinin ISIN kodu SE0009973563’dir.

XSpray Pharma AB (publ) 'nin WKN'si A2H48J 'dir.

XSpray Pharma AB (publ) için Ticker XSPRAY.ST’dir.

Son 12 ay içerisinde XSpray Pharma AB (publ), tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için XSpray Pharma AB (publ), tahmini olarak 0 SEK tutarında bir temettü ödemesi yapacak.

XSpray Pharma AB (publ) şirketinin mevcut temettü verimi .

XSpray Pharma AB (publ) dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

XSpray Pharma AB (publ), son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 SEK tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

XSpray Pharma AB (publ), 'Sağlık' sektörüne atanmıştır.

Son XSpray Pharma AB (publ) tarihinde 0 SEK tutarındaki en son temettüyü alabilmek için, hisseyi 07.01.2025 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 07.01.2025 olarak gerçekleşti.

2024 yılında XSpray Pharma AB (publ) tarafından 0 SEK olarak temettüler dağıtıldı.

XSpray Pharma AB (publ) hisselerinin temettüleri SEK olarak dağıtılır.